Growing proteomics and glycomics industry to drive the growth of global glycobiology market According to TechSci Research report, “Global Glycobiology Market By Product (Enzymes, Instruments, Reagents and Kits), By Application (Drug Discovery, Disease Diagnostics, Virology, Cell Biology, Oncology, Others), By End User (Research Institutes, Diagnostic Centers, Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, Others), By Company, By Region, Forecast & Opportunities, 2025”, the global glycobiology market was valued at USD 938.76 Million and is expected to grow at a formidable rate of 13.83% during the forecast period on account of the increasing R&D activities related to glycomics and proteomics. Additionally, ongoing technological advancements especially in the instrumentations and kits used in glycobiology technique coupled with the novel product launches by the major players operating in the market is further expected to propel the market during forecast period.
Also, the use of glycobiology in the anti-cancer drug discovery is anticipated to spur the growth of market over the next few years. Furthermore, the use of glycomics in the field of dermatology for studying the aging pattern of the skin is expected to positively impact the growth of market through 2025. Also, synthesis, differentiation and proliferation of skin can be achieved using glycobiology thereby increasing its application in tissue architecture. However, high costs of the instrumentation, tools or kits used in the technique make it expensive which can hamper the growth of market during forecast period. Additionally, stringent government policies also hinder the market growth. Moreover, the technique requires skilled personnel to perform it and lack of such skilled people might impede the growth of market over the next few years.
The global glycobiology market is segmented based on product, application, end user, company, and region. Based on by product, the market can be categorized into enzymes, instruments, reagents, and kits. The majority of market share is covered by enzymes of about 35%. Based on by kit, the market can be categorized into glycan releasing kit, glycan labelling kit, glycan purification kit and others. The glycan releasing kit segment is expected to dominate the market since these kits are applicable for different enzymes such as glycosyltransferases, sialyltransferases, sulfotransferases, among others that generate leaving groups with a removable phosphate. Additionally, these kits are quantitative, convenient and amenable to high throughput analysis. Based on application, the market can be fragmented into drug discovery, disease diagnostics, virology, cell biology, oncology and others. The drug discovery segment is expected to dominate the market on account of the increasing demand for personalized medicines. Additionally, increasing R&D activities by the major players operating in the market and different governments around the globe for the development of novel therapeutics is further anticipated to drive the growth of this segment during the next five years. Based on end user, the market can be grouped into research institutes, diagnostic centers, hospitals, clinical laboratories, pharmaceutical & biotechnology companies and others. The research institutes segment is expected to register highest CAGR during the forecast period. This can be accredited to the growing demand for new drug discovery and development especially for treatment of chronic diseases such as diabetes, cancer, among others.
Merck & Co., Inc., Agilent Technologies, Inc., Thermo Fisher Scientific, New England Biolabs, Inc., Shimadzu Corporation, Takara Bio Inc., Waters Corporation, Asparia Glycomics S.L., Bruker Corporation, RayBiotech, Inc., Z Biotech, LLC., Chemily Glycoscience, Dextra Laboratories Ltd., Lectenz Bio, Ludger Ltd, R&D Systems, Inc., Glycotope GmbH, Danaher Corporation, S-BIO (subsidiary of Sumitomo Bakelite Co. Ltd., Japan), Bio-Rad Laboratories and others are some of the leading players operating in global glycobiology market. The companies operating in the market are using organic strategies such as product launches, mergers and collaborations to boost their share. For instance, in June 2019, Agilent Technologies (US) launched InfinityLab LC/MSD iQ System.
“Asia Pacific is expected to register significant growth in the glycobiology market during the forecast period, owing to the increasing funding on glycomics research, rising R&D expenditure for drug discovery & development, among others. Additionally, increasing number of biopharmaceutical and pharmaceutical companies in the region is further expected to create lucrative opportunities for the market players over the next few years.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“Global Glycobiology Market By Product (Enzymes, Instruments, Reagents and Kits), By Application (Drug Discovery, Disease Diagnostics, Virology, Cell Biology, Oncology, Others), By End User (Research Institutes, Diagnostic Centers, Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, Others), By Company, By Region, Forecast & Opportunities, 2025”,” has evaluated the future growth potential of global glycobiology market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in global glycobiology market.
For more information, visit www.techsciresearch.com
